Trials / Unknown
UnknownNCT00098358
Study of Oral Zileuton in the Treatment of Moderate to Severe Facial Acne Vulgaris
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Clinical Proof of Concept Study of Zileuton IR in Patients With Moderate to Severe Facial Acne Vulgaris
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (planned)
- Sponsor
- Critical Therapeutics · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
Tissue inflammation is a major component of the acne disease process. Leukotriene B4 (LTB4) is thought to be a major player in the development of tissue inflammation. Synthesis of LTB4 is controlled by the enzyme 5-lipoxygenase. Zileuton blocks the activity of 5-lipoxygenase. This study will test the safety and efficacy of zileuton in the treatment of facial acne.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zileuton |
Timeline
- Start date
- 2004-11-01
- Completion
- 2005-05-01
- First posted
- 2004-12-08
- Last updated
- 2007-02-07
Locations
12 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00098358. Inclusion in this directory is not an endorsement.